Acumen Pharmaceuticals (ABOS) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TScan Therapeutics (TCRX) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 84.8% versus a loss of 88.1%. Over five years, ABOS leads with a -97.7% price change compared with -98.3% for TCRX. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $9.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | TCRX |
|---|---|---|
| Share price | $0.1865 | $0.1459 |
| Market cap | $13.49M | $9.89M |
| 1-day change | -3.52% | +2.24% |
| YTD return | -91.16% | -85.41% |
| 1-year return | -88.12% | -84.85% |
| 5-year return | -97.74% | -98.33% |
| EPS (TTM) | $-1.55 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.32M |
| Revenue growth (YoY) | — | +266.65% |
| Net income (latest FY) | $-121.33M | $-129.77M |
| Operating margin | — | -1315.38% |
| Net margin | — | -1256.81% |
| 52-week high | $3.60 | $1.47 |
| 52-week low | $0.16 | $0.14 |
| Distance from 52-week high | -94.82% | -90.07% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +3975.07% | +585.40% |
| Average volume | 2.73M | 766.11K |
| Shares outstanding | 72.33M | 63.50M |
| Employees | 60 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
ABOS vs TCRX FAQ
Which is bigger, Acumen Pharmaceuticals or TScan Therapeutics?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $9.89M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, ABOS or TCRX?
TCRX returned -84.85% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.